ALLON COMPLETES PATIENT DOSING FOR AL-208

Allon Therapeutics has completed patient dosing for a Phase Ib human clinical trial evaluating the safety, tolerability and pharmacokinetics of AL-208 as a treatment for neurodegenerative indications where multiple doses are required.

The company also expects to begin a Phase II trial within a month to evaluate AL-208 as a treatment for the mild cognitive impairment that occurs following coronary artery bypass graft (MCI post-CABG) surgery.